
Allergy company ALK is now the exclusive owner of the FDA-approved drug Otiprio, used for treating acute otitis media, also known as swimmer's ear, of which there are more than 4 million cases annually in the US spread out among 3.4 million patients.
CEO of ALK Carsten Hellmann confirms the news in the recently published quarterly report.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app